AngelNV winner Regara can cut lengthy FDA approval process in half

Las Vegas-based tech startup Regara can cut the time-consuming FDA approval process in half, which, for a drug like Ozempic, would be worth more than $100 billion in sales.

Original Source

Read the full article at Reviewjournal →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.